$MTVA
MetaVia Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022004958 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.581M $8.752M $1.740M
YoY Change 48.33% 11.49% -262.62%
% of Gross Profit
Research & Development $1.997M $6.546M $440.0K
YoY Change 353.86% 44.47% -73.01%
% of Gross Profit
Depreciation & Amortization $12.00K $48.00K $20.00K
YoY Change -40.0% 4.35% 100.0%
% of Gross Profit
Operating Expenses $4.578M $6.546M $2.180M
YoY Change 110.0% 44.47% 296.36%
Operating Profit -$15.30M
YoY Change -48.52%
Interest Expense $0.00 $14.00K $10.00K
YoY Change -100.0% -65.0% -98.73%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$4.578M -$15.28M -$19.51M
YoY Change -76.54% -48.5% 74.82%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.578M -$15.28M -$19.51M
YoY Change -76.54% -48.5% 74.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.66
Diluted Earnings Per Share -$173.0K -$0.66 -$1.185M
COMMON SHARES
Basic Shares Outstanding 26.59M 23.14M
Diluted Shares Outstanding 23.14M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.39M $16.39M $10.09M
YoY Change 62.41% 62.41% -27.46%
Cash & Equivalents $16.39M $16.39M $10.09M
Short-Term Investments
Other Short-Term Assets $197.0K $197.0K $48.00K
YoY Change 310.42% -67.17% -77.14%
Inventory
Prepaid Expenses $197.0K $546.0K
Receivables
Other Receivables
Total Short-Term Assets $16.58M $16.58M $10.68M
YoY Change 55.24% 55.28% -24.34%
LONG-TERM ASSETS
Property, Plant & Equipment $110.0K $215.0K $155.0K
YoY Change -29.03% -25.86% -55.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $155.0K
YoY Change
Total Long-Term Assets $215.0K $215.0K $285.0K
YoY Change -24.56% -25.86% -18.57%
TOTAL ASSETS
Total Short-Term Assets $16.58M $16.58M $10.68M
Total Long-Term Assets $215.0K $215.0K $285.0K
Total Assets $16.80M $16.80M $10.97M
YoY Change 53.16% 53.14% -24.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $830.0K $830.0K $2.575M
YoY Change -67.77% -67.83% 302.34%
Accrued Expenses $1.301M $1.327M $1.096M
YoY Change 18.7% 18.48% -23.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.157M $2.157M $3.695M
YoY Change -41.62% -41.7% 77.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $45.00K $45.00K $70.00K
YoY Change -35.71% -35.71% -22.22%
Total Long-Term Liabilities $45.00K $45.00K $70.00K
YoY Change -35.71% -35.71% -22.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.157M $2.157M $3.695M
Total Long-Term Liabilities $45.00K $45.00K $70.00K
Total Liabilities $2.202M $2.202M $3.765M
YoY Change -41.51% -41.59% 72.71%
SHAREHOLDERS EQUITY
Retained Earnings -$81.83M -$66.54M
YoY Change 22.97%
Common Stock $27.00K $20.00K
YoY Change 35.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.60M $14.60M $7.203M
YoY Change
Total Liabilities & Shareholders Equity $16.80M $16.80M $10.97M
YoY Change 53.16% 53.14% -24.2%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$4.578M -$15.28M -$19.51M
YoY Change -76.54% -48.5% 74.82%
Depreciation, Depletion And Amortization $12.00K $48.00K $20.00K
YoY Change -40.0% 4.35% 100.0%
Cash From Operating Activities -$2.899M -$15.13M -$2.340M
YoY Change 23.89% 40.6% 82.81%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $3.000K $0.00
YoY Change -25.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$583.0K -$583.0K $70.00K
YoY Change -932.86% -932.86% -101.2%
Cash From Investing Activities -$583.0K -$586.0K $70.00K
YoY Change -932.86% -949.28% -101.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.89M 22.03M 0.000
YoY Change 221.17%
NET CHANGE
Cash From Operating Activities -2.899M -15.13M -2.340M
Cash From Investing Activities -583.0K -586.0K 70.00K
Cash From Financing Activities 12.89M 22.03M 0.000
Net Change In Cash 9.404M 6.306M -2.270M
YoY Change -514.27% -264.35% -68.56%
FREE CASH FLOW
Cash From Operating Activities -$2.899M -$15.13M -$2.340M
Capital Expenditures $0.00 $3.000K $0.00
Free Cash Flow -$2.899M -$15.14M -$2.340M
YoY Change 23.89% 40.57% 96.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.83
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23143792
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16217339
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001638287
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26661771
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19671182
CY2021 nrbo Defined Contribution Plan Employer Matching Contribution Vesting Percentage
DefinedContributionPlanEmployerMatchingContributionVestingPercentage
P6Y
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37809
CY2021 dei Entity Registrant Name
EntityRegistrantName
NeuroBo Pharmaceuticals, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2389984
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Berkeley Street, Office 19th Floor
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2021 dei City Area Code
CityAreaCode
857
CY2021 dei Local Phone Number
LocalPhoneNumber
702-9600
CY2021 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2021 dei Trading Symbol
TradingSymbol
NRBO
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
31200000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26661771
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16387000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10089000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
197000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
546000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
48000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
16584000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
10683000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
105000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
130000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155000
CY2021Q4 us-gaap Assets
Assets
16799000
CY2020Q4 us-gaap Assets
Assets
10968000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
830000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2575000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1301000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1096000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2157000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3695000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
70000
CY2021Q4 us-gaap Liabilities
Liabilities
2202000
CY2020Q4 us-gaap Liabilities
Liabilities
3765000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26661771
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19671182
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96394000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
73713000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81828000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66544000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14597000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7203000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16799000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10968000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6546000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4531000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8752000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7846000
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
17339000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
15298000
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
29716000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-15298000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-29716000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
14000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
39000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15284000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29678000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15284000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29678000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15294000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29676000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.83
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23143792
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16217339
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
12292000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7500000
CY2020 nrbo Adjustments To Additional Paid In Capital Transaction Costs In Connection With Equity Financing
AdjustmentsToAdditionalPaidInCapitalTransactionCostsInConnectionWithEquityFinancing
984000
CY2020 nrbo Adjustments To Additional Paid In Capital Issuance Of Broker Warrants In Connection With Equity Financing
AdjustmentsToAdditionalPaidInCapitalIssuanceOfBrokerWarrantsInConnectionWithEquityFinancing
289000
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
17030000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
699000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
53000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
2000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29678000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7203000
CY2021 nrbo Stock And Warrants Issued During Period Value
StockAndWarrantsIssuedDuringPeriodValue
24000000
CY2021 nrbo Adjustments To Additional Paid In Capital Transaction Costs In Connection With Equity Financing
AdjustmentsToAdditionalPaidInCapitalTransactionCostsInConnectionWithEquityFinancing
2089000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
115000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
662000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-10000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15284000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14597000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15284000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29678000
CY2020 nrbo In Process Research And Development Exchanged For Common Stock
InProcessResearchAndDevelopmentExchangedForCommonStock
17339000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
662000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
699000
CY2021 nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
24000
CY2020 nrbo Increase Decrease In Non Cash Lease Expense
IncreaseDecreaseInNonCashLeaseExpense
21000
CY2021 us-gaap Depreciation
Depreciation
48000
CY2020 us-gaap Depreciation
Depreciation
46000
CY2021 nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
-396000
CY2020 nrbo Increase Decrease In Prepaid Expenses And Deposits
IncreaseDecreaseInPrepaidExpensesAndDeposits
-33000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1162000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1123000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
182000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10764000
CY2020 nrbo Proceeds Acquired In Connection With Merger
ProceedsAcquiredInConnectionWithMerger
180000
CY2021 nrbo Payments For Transaction Costs In Connection With Merger
PaymentsForTransactionCostsInConnectionWithMerger
583000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-347000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15134000
CY2020 nrbo Payments For Transaction Costs In Connection With Merger
PaymentsForTransactionCostsInConnectionWithMerger
107000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-586000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69000
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
24000000
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
7500000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
2089000
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
695000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
115000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
53000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22026000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6858000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6306000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3837000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-8000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10089000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13923000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16387000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10089000
CY2020 nrbo Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued Value
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssuedValue
17030000
CY2020Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
201000
CY2020 us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
583000
CY2020 us-gaap Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
289000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16400000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81800000
CY2022Q1 nrbo Number Of Consecutive Compliance Business Days
NumberOfConsecutiveComplianceBusinessDays
P10D
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgements about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company’s cash is principally held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of December 31, 2021, the Company had deposits in excess of federally insured amounts by $16.0 million.</p>
CY2021Q4 nrbo Deposits In Excess Of Federally Insured Amounts
DepositsInExcessOfFederallyInsuredAmounts
16000000.0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.10
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
439126
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
1.35
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
771667
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.97
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
180000
CY2021Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
201000
CY2021Q4 nrbo Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Of Research And Development Project
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessOfResearchAndDevelopmentProject
17339000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1166000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30754000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
17720000
CY2021Q4 nrbo Percentage Of Royalty Payments
PercentageOfRoyaltyPayments
0.025
CY2021Q4 nrbo Royalty Payment Accrued
RoyaltyPaymentAccrued
0
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26748000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
20000
CY2021Q4 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
854000
CY2020Q4 nrbo Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
218000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
376000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
277000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
59000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
561000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1301000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1096000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
276000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
161000
CY2021Q4 nrbo Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
17000
CY2020Q4 nrbo Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
24000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
44000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
52000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1483000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
221000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
218000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
111000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
63000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
155000
CY2019Q4 nrbo Percentage Of Proceeds From Grant Sale Or Transfer Of Rights
PercentageOfProceedsFromGrantSaleOrTransferOfRights
0.80
CY2019Q4 nrbo Percentage Of Proceeds From Grant Sale Or Transfer Of Rights
PercentageOfProceedsFromGrantSaleOrTransferOfRights
0.80
CY2021Q1 nrbo Percentage Of Proceeds From Grant Sale Or Transfer Of Rights
PercentageOfProceedsFromGrantSaleOrTransferOfRights
0.10
CY2021Q4 nrbo Milestones Accrued
MilestonesAccrued
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
676666
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
95000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
32000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
32000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
80000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
71000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
78055
CY2021Q4 nrbo Class Of Warrants Or Rights Exercisable
ClassOfWarrantsOrRightsExercisable
78055
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6885748
CY2020Q4 nrbo Class Of Warrants Or Rights Exercisable
ClassOfWarrantsOrRightsExercisable
2578055
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
662000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
699000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
639000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
364000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
629127
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.48
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.774
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0151
CY2020 nrbo Valuation Allowance Of Foreign Income Tax Expense Benefit
ValuationAllowanceOfForeignIncomeTaxExpenseBenefit
-95000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19904000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14052000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
324000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
243000
CY2021Q4 nrbo Deferred Tax Assets Acquired Intangibles
DeferredTaxAssetsAcquiredIntangibles
8706000
CY2020Q4 nrbo Deferred Tax Assets Acquired Intangibles
DeferredTaxAssetsAcquiredIntangibles
11050000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.035
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.019
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.123
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.262
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.443
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.342
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.008
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14954000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-29297000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-330000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-381000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15284000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29678000
CY2021 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-3932000
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
-13059000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-81000
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-95000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4013000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-13154000
CY2021 nrbo Valuation Allowance Of Domestic Income Tax Expense Benefit
ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit
-3932000
CY2020 nrbo Valuation Allowance Of Domestic Income Tax Expense Benefit
ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit
-13059000
CY2021 nrbo Valuation Allowance Of Foreign Income Tax Expense Benefit
ValuationAllowanceOfForeignIncomeTaxExpenseBenefit
-81000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
27000
CY2021Q4 nrbo Deferred Tax Liabilities Rou Asset
DeferredTaxLiabilitiesRouAsset
18000
CY2020Q4 nrbo Deferred Tax Liabilities Rou Asset
DeferredTaxLiabilitiesRouAsset
24000
CY2021Q4 nrbo Deferred Tax Liabilities Lease Liabilities And Other
DeferredTaxLiabilitiesLeaseLiabilitiesAndOther
2000
CY2020Q4 nrbo Deferred Tax Liabilities Lease Liabilities And Other
DeferredTaxLiabilitiesLeaseLiabilitiesAndOther
3000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30800000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26700000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30800000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26700000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
81800000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
57500000
CY2021Q4 nrbo Operating Loss Carry Forward Research Credit
OperatingLossCarryForwardResearchCredit
1000000.0
CY2020Q4 nrbo Operating Loss Carry Forward Research Credit
OperatingLossCarryForwardResearchCredit
700000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
42600000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
25100000
CY2021Q4 nrbo Deferred Tax Assets Tax Credit Carryforwards State
DeferredTaxAssetsTaxCreditCarryforwardsState
600000
CY2020Q4 nrbo Deferred Tax Assets Tax Credit Carryforwards State
DeferredTaxAssetsTaxCreditCarryforwardsState
500000
CY2021 nrbo Threshold Percentage Of Shareholders Ownership Change
ThresholdPercentageOfShareholdersOwnershipChange
0.05
CY2021 nrbo Minimum Increase In Ownership Percentage Annual Limitation May Result In Expiration Of Net Operating Losses And Credits
MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits
0.50
CY2021 nrbo Period For Testing Percentage Of Ownership Change
PeriodForTestingPercentageOfOwnershipChange
P36M
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 nrbo Defined Contribution Plan Employee Eligibility Age
DefinedContributionPlanEmployeeEligibilityAge
P21Y
CY2021 nrbo Employee Compensation Vesting Percentage On Contribution
EmployeeCompensationVestingPercentageOnContribution
1
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0001558370-22-004958-index-headers.html Edgar Link pending
0001558370-22-004958-index.html Edgar Link pending
0001558370-22-004958.txt Edgar Link pending
0001558370-22-004958-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrbo-20211231.xsd Edgar Link pending
nrbo-20211231x10k.htm Edgar Link pending
nrbo-20211231x10k001.jpg Edgar Link pending
nrbo-20211231x10k002.jpg Edgar Link pending
nrbo-20211231x10k003.jpg Edgar Link pending
nrbo-20211231x10k004.jpg Edgar Link pending
nrbo-20211231x10k005.jpg Edgar Link pending
nrbo-20211231x10k006.jpg Edgar Link pending
nrbo-20211231x10k007.jpg Edgar Link pending
nrbo-20211231x10k008.jpg Edgar Link pending
nrbo-20211231x10k009.jpg Edgar Link pending
nrbo-20211231x10k_htm.xml Edgar Link completed
nrbo-20211231xex10d47.htm Edgar Link pending
nrbo-20211231xex10d47002.jpg Edgar Link pending
nrbo-20211231xex10d48.htm Edgar Link pending
nrbo-20211231xex10d48002.jpg Edgar Link pending
nrbo-20211231xex21d1.htm Edgar Link pending
nrbo-20211231xex23d1.htm Edgar Link pending
nrbo-20211231xex31d1.htm Edgar Link pending
nrbo-20211231xex32d1.htm Edgar Link pending
nrbo-20211231_cal.xml Edgar Link unprocessable
nrbo-20211231_def.xml Edgar Link unprocessable
nrbo-20211231_lab.xml Edgar Link unprocessable
nrbo-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending